Autonomic Dysreflexia
Autonomic dysreflexia (AD) is a potentially life-threatening syndrome of uncontrolled sympathetic discharge triggered by a noxious stimulus below the level of a spinal-cord injury (SCI), most commonly arising at or above the T6 level. It manifests as acute, severe hypertension with reflex compensatory parasympathetic activation above the lesion (bradycardia, headache, flushing, sweating). The dominant trigger across all SCI series is urinary — bladder distension, catheter blockage, urinary tract infection, or urologic procedures — making AD recognition and prevention central to the urologic care of any SCI patient with a lesion T6 or above.[1][2][3]
For the broader NLUTD framework see the Neurogenic Lower Urinary Tract Dysfunction section. For urodynamics in this population see Urodynamics. For the surgical interventions that depend on AD-aware perioperative management see Sacral Neuromodulation, Intradetrusor OnabotulinumtoxinA, and Augmentation Cystoplasty.
Definition and Epidemiology
The International Standards on AD (Krassioukov 2012; reaffirmed by ASIA / ISCoS) define AD as a sustained rise in systolic blood pressure of ≥ 20 mmHg above baseline in patients with SCI at or above T6, in the presence of a noxious stimulus.[4]
| Parameter | Detail |
|---|---|
| Prevalence in T6 and above SCI | 48–90% depending on case definition and population[2][5] |
| Median time to first episode | Within first 6 months post-injury |
| Lesion-level threshold | T6 and above — splanchnic sympathetic outflow (T5–L2) split off from supraspinal control |
| Below T6 | AD is rare and generally less severe; isolated reports in T7–T10 lesions |
| Trigger distribution | Urinary 75–85% > bowel 10–20% > cutaneous / pressure ulcer / fracture / DVT / labor |
Pathophysiology
The pathophysiologic substrate is a disconnection of supraspinal inhibitory control from the sympathetic outflow that supplies the splanchnic vasculature (T5–L2). When a noxious stimulus enters the cord below the lesion, it triggers a massive, unopposed sympathetic discharge. Above the lesion, baroreceptor activation drives a parasympathetic counter-response — but the parasympathetic limb cannot cross the lesion to inhibit the runaway sympathetic outflow below.[1][3]
| Below the lesion | Above the lesion |
|---|---|
| Massive sympathetic discharge → vasoconstriction, severe hypertension | Compensatory parasympathetic activation |
| Pale, cool skin; piloerection | Vagally-mediated bradycardia (paradoxical given the BP) |
| Splanchnic vasoconstriction | Flushing, sweating, blurred vision, nasal congestion |
| Pounding headache (the cardinal symptom) |
The gut and bladder are over-represented as triggers because their afferent fibers ascend densely through the splanchnic / hypogastric / pelvic nerve trunks — each is essentially a tripwire for the unopposed sympathetic loop.
Clinical Presentation
The classic syndrome combines acute hypertension (often 20–40 mmHg above the SCI baseline of ~ 90–110 mmHg systolic) with a pounding headache and a constellation of vasomotor and autonomic symptoms above and below the lesion.[1][6]
Above the lesion
- Pounding / throbbing headache — most common and most reliable symptom
- Flushing, profuse sweating (especially face, neck, upper torso)
- Nasal congestion
- Blurred vision, mydriasis
- Anxiety, sense of impending doom
- Bradycardia (paradoxical reflex)
Below the lesion
- Pale, cool, dry skin with piloerection ("goosebumps")
- Spasticity exacerbation
Severity spectrum
- Asymptomatic AD ("silent AD") — measurable BP elevation without symptoms; most common during routine urologic procedures (urodynamics, cystoscopy)[7]
- Symptomatic AD — the classic syndrome above
- Severe AD — systolic BP > 180 mmHg; risk of intracerebral hemorrhage, hypertensive encephalopathy, seizures, retinal hemorrhage, myocardial ischemia, pulmonary edema, and death[1][6]
Common Triggers
The dominant trigger categories — by descending frequency:[1][2][3]
| Category | Specific triggers |
|---|---|
| Urinary (75–85%) | Bladder distension (kinked catheter, blocked supra-pubic tube, retention from CIC overdue), UTI, bladder stones, urodynamics, cystoscopy, intradetrusor botulinum-toxin injection, ESWL, urethral catheterization, prostate stimulation / vibrostimulation for sperm retrieval |
| Bowel (10–20%) | Fecal impaction, flatulence, anal fissure, hemorrhoids, digital rectal exam, enema, anorectal procedure |
| Cutaneous | Pressure ulcer, ingrown toenail, burns, tight clothing |
| Skeletal / orthopedic | Long-bone fracture, heterotopic ossification |
| Vascular | DVT, thrombophlebitis |
| Reproductive | Labor / delivery, menstrual cramps, ejaculation, vibrostimulation, electroejaculation |
| Pharmacologic | Misoprostol; sympathomimetics; abrupt withdrawal of clonidine or baclofen |
Acute Management
The Consortium for Spinal Cord Medicine clinical practice guideline establishes the standard acute approach:[6][8]
1. Position upright
- Sit the patient up immediately — orthostatic effect drops BP by 10–20 mmHg through gravity-dependent venous pooling below the lesion.
- Loosen tight clothing or constrictive devices (binders, abdominal binders, support stockings).
2. Identify and remove the trigger — bladder first
Because urinary triggers dominate, the bladder is checked first:
| Catheter status | Action |
|---|---|
| No catheter, can't void | Insert urethral catheter using 2% lidocaine jelly (the lubricant itself reduces the AD response); drain slowly to avoid rebound hypotension |
| Indwelling catheter present | Check for kinks, clots, sediment occlusion; irrigate gently with 10–15 mL warm saline |
| Suprapubic tube | Same — confirm patency; replace if blocked |
| CIC schedule overdue | Catheterize immediately |
If the bladder is the trigger and is now drained, BP often falls within minutes. If BP remains elevated, proceed to bowel disimpaction (lidocaine jelly into the rectum first to reduce afferent input), then check skin and other triggers.
3. Pharmacologic BP reduction
If BP remains ≥ 150 mmHg systolic after positioning and trigger removal:[6]
| Agent | Dose | Notes |
|---|---|---|
| Nitroglycerin paste | 1 inch (2.5 cm) above the lesion | First-line; easily wiped off if BP overshoots — this on/off control matters more than potency |
| Nifedipine immediate-release | 10 mg (chew-and-swallow or sublingual) | Older first-line; concerns about precipitous drop |
| Captopril | 25 mg sublingual | Alternative |
| Hydralazine | 5–10 mg IV | When IV access is needed |
| Labetalol | 10–20 mg IV | Useful in severe / refractory AD |
Critical caveat: patients on chronic PDE5 inhibitors for ED cannot receive nitroglycerin or nitrate paste — risk of severe hypotension. Use a non-nitrate alternative.[6]
4. Continuous BP and HR monitoring
- BP and HR every 2–5 minutes until baseline is restored.
- Once resolved, continue monitoring for 2 hours to detect rebound hypertension or recurrent AD from a persistent trigger.
Prevention in Urologic Practice
Because the bladder is the dominant trigger, urologic-procedure planning is the single most important AD-prevention domain.
Routine outpatient procedures
| Procedure | AD-prevention strategy |
|---|---|
| CIC | Patient education on schedule adherence; technique; lidocaine jelly |
| Indwelling catheter exchanges | Pre-procedure lidocaine; drain slowly; exchange under sterile conditions |
| Cystoscopy | Pre-procedure 2% lidocaine jelly with 5–10 min dwell time; consider prophylactic nifedipine 10 mg sublingual or topical NTG paste in patients with documented AD[7] |
| Urodynamics | Continuous BP monitoring during filling; abort if AD develops; document baseline AD susceptibility on the report[7][9] |
| Intradetrusor BoNT-A | Pre-procedure NTG paste in known AD-susceptible patients; continuous BP monitoring; have nifedipine immediately available |
| ESWL / cystolitholapaxy | Anesthesia / sedation with continuous BP monitoring; postprocedural hypertension surveillance |
| Vibrostimulation / electroejaculation for fertility | Pretreatment with nifedipine 30 mg sublingual 15 min before stimulation per ASIA / ISCoS protocols[10] |
Surgical procedures
| Setting | Considerations |
|---|---|
| Sacral neuromodulation | AD has been reported during stage 1 / 2 procedures; discuss with anesthesia; intraoperative arterial-line BP monitoring in T6-and-above patients[11] |
| Augmentation cystoplasty | Significant AD risk during bladder mobilization and distension; arterial-line monitoring; regional vs general anesthesia decision driven by AD susceptibility and respiratory function |
| Bladder neck reconstruction / closure | High AD risk; arterial-line standard of care |
| Renal stone surgery | PCNL / ureteroscopy positioning effects; intraoperative AD reported during ureteric manipulation |
Long-term prevention
- Optimize bladder management — convert PVR-positive patients to CIC; treat NDO (anticholinergics, β3-agonists, intradetrusor BoNT-A); augmentation cystoplasty for refractory NDO
- Treat recurrent UTI aggressively — UTI is the second-most-common urinary AD trigger after distension
- Bowel program — prevent fecal impaction with scheduled bowel care
- Skin surveillance — pressure-ulcer prevention
- Patient and caregiver education — every SCI patient and family should know the AD-recognition triad (headache + hypertension + autonomic symptoms) and the home algorithm
Special Populations
Pregnancy and labor
AD can complicate labor in SCI women and is a recognized cause of intracerebral hemorrhage in this population. Epidural anesthesia is the prevention of choice for labor in T6-and-above SCI; regional anesthesia blocks the afferent loop that drives the unopposed sympathetic discharge.[12]
Pediatric SCI
AD presents similarly in children but baseline BP is lower; the 20-mmHg-rise threshold still applies. Children with myelomeningocele rarely develop AD because lesion levels are usually below T6.[13]
Athletes — "boosting"
A doping-related concern: some Paralympic athletes have intentionally induced AD ("boosting") to improve performance through the secondary BP / cardiac-output effect. The IPC banned the practice in 2008 given the cerebrovascular risk. Urologists should be aware as a counseling topic.[14]
Differential Diagnosis
Acute hypertension in an SCI patient is AD until proven otherwise, but clinically differentiate:
- Pre-existing essential hypertension — chronic, not triggered, no headache
- Hypertensive emergency — usually no clear noxious trigger
- Pulmonary embolism — hypoxia, tachycardia (vs the bradycardia of AD)
- Acute coronary syndrome — chest discomfort if sensation preserved
- Sepsis — fever, tachycardia, hypotension trajectory
- Substance / sympathomimetic ingestion
Complications and Outcomes
Untreated severe AD carries serious morbidity:
| Complication | Mechanism |
|---|---|
| Intracerebral hemorrhage | Acute hypertensive cerebrovascular event |
| Hypertensive encephalopathy / seizures | Cerebral autoregulation failure |
| Retinal hemorrhage | Microvascular rupture |
| Pulmonary edema | Acute LV afterload mismatch |
| Myocardial ischemia / infarction | Coronary supply-demand mismatch |
| Death | Reported at all severity tiers but rare with prompt management |
With recognition and the position-bladder-then-pharmacology algorithm, most AD episodes resolve within minutes. The cumulative cardiovascular toll of recurrent AD over a lifetime is the more chronic concern — driving the long-term-prevention emphasis on bladder optimization.[1][3]
Key Takeaways
- AD is a urologic disease in functional terms — > 75% of triggers are bladder-derived. The bladder is the first place to look in any AD episode.
- Recognition triad — sudden severe hypertension + pounding headache + a noxious trigger below a T6-or-above SCI lesion.
- Sit-up first; bladder second; pharmacology third. Most episodes resolve at step 1 or 2.
- Lidocaine jelly is the simplest pre-procedure prophylaxis — it costs almost nothing and prevents many episodes.
- Nitrate-containing rescues are contraindicated in patients on PDE5 inhibitors — use an alternative agent.
- Document AD susceptibility on every urodynamics, cystoscopy, and operative report; the next provider needs to know.
- Long-term prevention is bladder management — CIC adherence, NDO control, UTI treatment, augmentation when refractory.
See Also
- Neurogenic Lower Urinary Tract Dysfunction (NLUTD) — section overview
- Urodynamics
- Sacral Neuromodulation
- Intradetrusor OnabotulinumtoxinA
- Augmentation Cystoplasty
- Erectile Dysfunction — PDE5i and nitrate-rescue interaction
- Geriatric Urology
References
1. Krassioukov A, Warburton DE, Teasell R, Eng JJ; Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil. 2009;90(4):682–95. doi:10.1016/j.apmr.2008.10.017
2. Helkowski WM, Ditunno JF Jr, Boninger M. Autonomic dysreflexia: incidence in persons with neurologically complete and incomplete tetraplegia. J Spinal Cord Med. 2003;26(3):244–7. doi:10.1080/10790268.2003.11753691
3. Eldahan KC, Rabchevsky AG. Autonomic dysreflexia after spinal cord injury: systemic pathophysiology and methods of management. Auton Neurosci. 2018;209:59–70. doi:10.1016/j.autneu.2017.05.002
4. Krassioukov A, Biering-Sørensen F, Donovan W, et al. International standards to document remaining autonomic function after spinal cord injury. J Spinal Cord Med. 2012;35(4):201–10. doi:10.1179/1079026812Z.00000000053
5. Curt A, Nitsche B, Rodic B, Schurch B, Dietz V. Assessment of autonomic dysreflexia in patients with spinal cord injury. J Neurol Neurosurg Psychiatry. 1997;62(5):473–7. doi:10.1136/jnnp.62.5.473
6. Consortium for Spinal Cord Medicine. Acute management of autonomic dysreflexia: individuals with spinal cord injury presenting to health-care facilities. J Spinal Cord Med. 2002;25 Suppl 1:S67–88. doi:10.1080/10790268.2002.11753628
7. Linsenmeyer TA, Campagnolo DI, Chou IH. Silent autonomic dysreflexia during voiding in men with spinal cord injuries. J Urol. 1996;155(2):519–22.
8. Solinsky R, Kirshblum SC, Burns SP. Exploring detailed characteristics of autonomic dysreflexia. J Spinal Cord Med. 2018;41(5):549–55. doi:10.1080/10790268.2017.1360434
9. Liu N, Zhou MW, Biering-Sørensen F, Krassioukov AV. Cardiovascular response during urodynamics in individuals with spinal cord injury. Spinal Cord. 2017;55(3):279–84. doi:10.1038/sc.2016.110
10. Steinberger RE, Ohl DA, Bennett CJ, McCabe M, Wang SC. Nifedipine pretreatment for autonomic dysreflexia during electroejaculation. Urology. 1990;36(3):228–31. doi:10.1016/0090-4295(90)80261-k
11. Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol. 2010;67(1):74–84. doi:10.1002/ana.21814
12. ACOG Committee on Obstetric Practice. ACOG Committee Opinion: obstetric management of patients with spinal cord injuries. Obstet Gynecol. 2002;100(3):625–7.
13. Hickey KJ, Vogel LC, Willis KM, Anderson CJ. Prevalence and etiology of autonomic dysreflexia in children with spinal cord injuries. J Spinal Cord Med. 2004;27 Suppl 1:S54–60. doi:10.1080/10790268.2004.11753787
14. Mazzeo F, Santamaria S, Iavarone A. "Boosting" in Paralympic athletes with spinal cord injury: doping without drugs. Funct Neurol. 2015;30(2):91–8.